To ensure that a patient’s test is billed to their 2024 health benefits, testing must be started before the end of the year. For exome, genome, or Xpanded testing, if you do not expect parental samples to be received before the end of the year, please contact us at support@genedx.com to determine how to proceed.
Chief Financial Officer
Kevin Feeley has more than 20 years of finance and accounting leadership experience in the healthcare, pharmaceutical, and diagnostics sectors. As Chief Financial Officer at GeneDx, Kevin leads financial strategy, management, and planning. Kevin is also responsible for key operational aspects of the company, including lab network operations, supply chain, and genetic counseling services.
Previously, Kevin served as Chief Financial Officer of OPKO Health’s rapidly growing diagnostics division for six years, which included BioReference Laboratories, Inc. and GeneDx. During the COVID-19 pandemic, Kevin led the operational design and execution of BioReference’s sports diagnostic program serving all four major sports leagues in the U.S.
Before that, Kevin was U.S. Controller at Reckitt Benckiser, a global consumer packaged goods company focused on health, hygiene, and nutrition brands. He also previously led SEC reporting at Bausch Health Companies, a public specialty pharmaceutical company, and spent twelve years in the audit practice of KPMG LLP working closely with large multinational pharmaceutical companies.
Kevin is a Certified Public Accountant and holds a BBA in Accounting from James Madison University.
